Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Insight Molecular Diagnostics's 10-Year RORE % for the quarter that ended in Mar. 2026 was -9.60%.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Insight Molecular Diagnostics 10-Year RORE % Related Terms
Insight Molecular Diagnostics 10-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Insight Molecular Diagnostics's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insight Molecular Diagnostics 10-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Insight Molecular Diagnostics's 10-Year RORE % distribution charts can be found below:
* The bar in red indicates where Insight Molecular Diagnostics's 10-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 10-year before.
Insight Molecular Diagnostics (IMDX) has a 10-Year RORE % of -9.60 as of Mar. 2026. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Insight Molecular Diagnostics and its competitors. According to the industry distribution chart, Insight Molecular Diagnostics ranks #83 out of 121 companies in the Medical Diagnostics & Research industry, placing it in the top 68.6%.
Is Insight Molecular Diagnostics' 10-Year RORE % too high?
Insight Molecular Diagnostics' current 10-Year RORE % is -9.60. Based on the distribution chart, Insight Molecular Diagnostics ranks #83 out of 121 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Insight Molecular Diagnostics has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Insight Molecular Diagnostics' 10-Year RORE % compare to XGN and BDSX?
According to the Medical Diagnostics & Research industry distribution chart, Insight Molecular Diagnostics ranks #83 out of 121 companies for 10-Year RORE %. This places Insight Molecular Diagnostics in the lower half of its industry. The industry median 10-Year RORE % is 0.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Medical Diagnostics & Research company?
The median 10-Year RORE % among Medical Diagnostics & Research companies is 0.83, based on 121 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Insight Molecular Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median 10-Year RORE % is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insight Molecular Diagnostics's current 10-Year RORE % is -9.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insight Molecular Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Insight Molecular Diagnostics (IMDX) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $5.69 — trading 355.2% above its estimated fair value. The current 10-Year RORE % is -9.60. Insight Molecular Diagnostics' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Insight Molecular Diagnostics (IMDX), the current 10-Year RORE % is -9.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insight Molecular Diagnostics (IMDX) Overvalued in 2026?
Based on GuruFocus' analysis, Insight Molecular Diagnostics stock appears to be overvalued.
The current stock price of $5.69 is trading 355.2% above its estimated GF Value™ of $1.25.
GuruFocus considers Insight Molecular Diagnostics to be Significantly Overvalued.
Key valuation signals for IMDX:
10-Year RORE %: -9.60
GF Value™: $1.25 vs. price of $5.69 (355.2% above fair value)
No single metric tells the full story. See the IMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insight Molecular Diagnostics Business Description
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
49GF Score
Get the complete analysis for IMDX
10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMDX has been successfully added to your 
